Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $63.99, for a total transaction of $10,638,337.50. Following the sale, the chief executive officer owned 8,974,783 shares of the company’s stock, valued at $574,296,364.17. The trade was a 1.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tempus AI Stock Up 2.3%

Shares of TEM stock traded up $1.46 during trading hours on Monday, reaching $65.92. 4,162,938 shares of the company’s stock were exchanged, compared to its average volume of 10,597,559. The stock has a market cap of $11.73 billion, a PE ratio of -55.39 and a beta of 4.99. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The stock’s fifty day moving average price is $77.83 and its two-hundred day moving average price is $73.81.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. During the same period in the previous year, the firm posted ($0.46) earnings per share. The firm’s quarterly revenue was up 84.7% on a year-over-year basis. Research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current year.

Institutional Trading of Tempus AI

Several hedge funds have recently bought and sold shares of the company. Allworth Financial LP increased its holdings in shares of Tempus AI by 73.9% during the 3rd quarter. Allworth Financial LP now owns 798 shares of the company’s stock worth $64,000 after purchasing an additional 339 shares during the period. IFP Advisors Inc boosted its stake in Tempus AI by 140.1% in the third quarter. IFP Advisors Inc now owns 4,274 shares of the company’s stock worth $345,000 after purchasing an additional 2,494 shares in the last quarter. Swiss Life Asset Management Ltd bought a new stake in Tempus AI during the 3rd quarter worth about $349,000. EMC Capital Management acquired a new stake in shares of Tempus AI in the 3rd quarter valued at $297,000. Finally, Sunbelt Securities Inc. acquired a new position in Tempus AI during the 3rd quarter valued at about $52,000. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TEM. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. Piper Sandler cut their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Morgan Stanley boosted their target price on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Canaccord Genuity Group decreased their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Needham & Company LLC increased their price target on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and a consensus target price of $84.00.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.